ORGO Q1 2020 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$62M+8.1% YoY

Gross Profit

$43M69.6% margin

Operating Income

-$15M-24.4% margin

Net Income

-$16M-26.4% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-17.3%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$22M

Stock-Based Comp.

$209,000

Balance Sheet

Total Assets

$208M

Total Liabilities

$168M

Stockholders' Equity

$40M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$57M	+8.1%
Gross Profit	$43M	$40M	+7.0%
Operating Income	-$15M	-$12M	-24.4%
Net Income	-$16M	-$16M	-4.1%

Revenue Segments

Advanced Wound care

$51M83%

Surgical and Sports Medicine

$10M17%